Intraocular pressure-lowering combination therapies with prostaglandin analogues (Q38017728)

27 August 2017

title

Intraocular pressure-lowering combination therapies with prostaglandin analogues (English)

1 reference

27 August 2017

Florent Aptel

1 reference

27 August 2017

Christophe Chiquet

series ordinal

1 reference

27 August 2017

Jean-Paul Romanet

series ordinal

1 reference

27 August 2017

publication date

1 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

1355-1371

1 reference

Number of people with glaucoma worldwide

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Collaborative Initial Glaucoma Treatment Study: a summary of results to date

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Adherence and persistence with glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Determinants of adherence to glaucoma medical therapy in a long-term patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Preservatives in eyedrops: the good, the bad and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Additive intraocular pressure lowering effect of various medications with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Effect of latanoprost 0.005% and brimonidine 0.2% on intraocular pressure after phacoemulsification and intraocular lens implantation surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Cost analysis of glaucoma medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A comparison of the fixed combination of latanoprost and timolol with its individual components

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glauc

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634460-000000000-00000

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group

21 January 2018

1 reference

12 December 2020

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost.

1 reference

12 December 2020

A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Compliance in patients prescribed eyedrops for glaucoma

1 reference

12 December 2020

24-Hour control with a latanoprost-timolol fixed combination vs timolol alone

1 reference

12 December 2020

The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma

1 reference

12 December 2020

Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma

1 reference

12 December 2020

Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group

1 reference

12 December 2020

Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.

1 reference

12 December 2020

Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study

1 reference

12 December 2020

A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma

1 reference

12 December 2020

Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

12 December 2020

Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients

1 reference

12 December 2020

The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies

1 reference

12 December 2020

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate

1 reference

12 December 2020

Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Primary open-angle glaucoma

1 reference

12 December 2020

Considerations in glaucoma therapy: fixed combinations versus their component medications.

1 reference

12 December 2020

A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy.

1 reference

12 December 2020

Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost

1 reference

12 December 2020

Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%

1 reference

12 December 2020

Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma

1 reference

12 December 2020

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%.

1 reference

12 December 2020

Glaucoma medication persistence with a fixed combination versus multiple bottles

1 reference

12 December 2020

Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment

1 reference

12 December 2020

Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study

1 reference

12 December 2020

10.2165/11634460-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1053024884

0 references

1 reference